AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study NCT05735353 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: High-Speed Circuit Resistance Training
Description: three times per week; 45 minutes per session; 12-weeks
Study NCT05735353 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: High-Speed Multidirectional Yoga
Description: two times per week; 60 minutes per session; 12-weeks
Study NCT05417906 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Standard care
Description: Oral prednisolone for 5 days
Study NCT05417906 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Eosinophil-directed care
Description: Oral prednisolone for 5 days if eosinophil count is ≥ 0.300 x 10\^3/µL, or 3 days if eosinophil is \< 0.300 x 10\^3/µL
Study NCT05358223 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Music
Description: A standard music determined by us for the 1st and 4th groups will be played during the process.
Study NCT05358223 — intervention group
Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: TENS
Description: TENS device will be connected to the 3rd and 5th groups during the process and the process will be done in this way.
Study NCT05266534 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Terlipressin
Description: the efficacy of intramyometrial Terlipressin injection on hemoglobin level and decreasing blood loss in women undergoing open myomectomy
Study NCT05266534 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Carbetocin
Description: the efficacy of intramyometrial carbetocin injection on hemoglobin level and decreasing blood loss in women undergoing open myomectomy
Study NCT05266534 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Saline
Description: the efficacy of intramyometrial saline injection on hemoglobin level and decreasing blood loss in women undergoing open myomectomy
Study NCT06401655 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Financial Coaching for People living with Acquired Brain Injury (FC-ABI)
Description: This is an individualized, in-person 10-session financial coaching intervention program. Each session is 45-minutes. In total, participants will be asked to participate in up to 7 hours and 30 minutes of intervention time with a trained Occupational Therapist. Each session will happen 1-1.5 weeks apart and the financial coaching program will last over 3-4 months. The financial coaching sessions will only be offered in-person (at MBIA Winnipeg location, in their home, at the University of Manitoba/Banntyne Campus, or other community locations acceptable/consented by the participant).
Study NCT06113913 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Infliximab
Description: Weekly administration of subcutaneous infliximab.
Study NCT06113913 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Infliximab
Description: Bi-weekly administration of subcutaneous infliximab.
Study NCT06113913 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Infliximab
Description: Optimized dosing schedule of intravenous infliximab.
Study NCT06187337 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Maxillary expansion device
Description: The maxillary expansion device is a orthodontic appliance that is used to expand the maxilla in children.
Study NCT05927389 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Adapted Physical Activity program
Description: The Adaptated Physical Activity program consists of a Personalized Training Program adapted to each patient's condition and capacities
Study NCT04923412 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Pulmonary branch of vagus nerve preserved
Description: During the mediastinal lymph node dissection using minimally invasive surgery, efforts to preserve the pulmonary branch of vagus nerve is made.
Study NCT06435572 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Suction
Description: Each patient will be evaluated as both the experimental and control group. In the study, open suction applied to the patient will be evaluated as control, and closed suction will be considered as the experimental group. The first suction of the same patient during the day will be done as open suction, and the second suction will be done as closed suction.
Study NCT04879134 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Apomorphine Injectable Solution
Description: Patients will receive the treatment while they are in an OFF period, without the effect of any antiparkinsonian medication. For this study, the initial dose of apomorphine or placebo will be 2 mg. We selected an initial standardized dose based on the pharmacological characteristics of apomorphine. Assessments will be completed 30 and 60 minutes after the initial dose. At 60 minutes from the first dose, a 3 mg dose will be administered, and again, assessments will be completed after 30 and 60 minutes. The total given dosage will be 5 mg. Blood pressure and pulse will be checked every 20 minutes after injections.~Other Names:~Movapo
Study NCT06122155 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Transcranial direct current stimulation (Anodal)
Description: 20-minutes, 2 mA anodal tDCS delivering through two 5 cm x 7 cm electrodes
Study NCT04879134 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: 0.9% saline placebo injection~Other Names:~• Saline
Study NCT06122155 — intervention group
Intervention type: DEVICE
Group type: SHAM_COMPARATOR
Intervention: Transcranial direct current stimulation (Sham)
Description: 20-minutes, 0 mA anodal tDCS delivering through two 5 cm x 7 cm electrodes
Study NCT06124300 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Female Hormone Balance Supplement
Description: The product contains: Myo-Inositol D-Chiro Inositol Folic Acid Vitamin D Vitamin B12
Study NCT04855864 — intervention group
Intervention type: OTHER
Group type: OTHER
Intervention: Follow-up of BCR TKA
Description: Pre- and postoperative follow-up of patients treated with the BCR design by measuring PROMs, and clinical- and radiographic evaluation
Study NCT04855864 — intervention group
Intervention type: OTHER
Group type: OTHER
Intervention: Follow-up of BCS TKA
Description: Pre- and postoperative follow-up of patients treated with the BCS design by measuring PROMs, and clinical- and radiographic evaluation
Study NCT04855864 — intervention group
Intervention type: OTHER
Group type: OTHER
Intervention: Follow-up of PS TKA
Description: Pre- and postoperative follow-up of patients treated with the PS design by measuring PROMs, and clinical- and radiographic evaluation
Study NCT06135402 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Treatment with Monalisa Glide Laser
Description: 3 fractional laser treatment-sessions with Monalisa Glide
Study NCT06135402 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Treatment with Clobetasol
Description: Application of Clobetasol twice per week
Study NCT05496049 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Triburter
Description: Patients will have to repeat 50 ventilations (start with 20 repetitions in the first week, 30 in the second, 40 in the four week, and 50 in the last week) five days per day for four weeks. And they have to fill a calendar to ensurance the intervention.
Study NCT05496049 — intervention group
Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Incentive spirometry
Description: They will repeat 10 ventilations per 5 five times a day. Both interventions will be performed for 4 weeks. They have to fill a calendar to ensurance the intervention.
Study NCT06629467 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Cognitive-behavioral therapy for smoking cessation
Description: Treatment components will include psychoeducation on the consequences of tobacco use and the benefits of quitting; therapeutic commitment; self-monitoring of cigarette smoking; brief advice on healthy eating behaviors and sleep hygiene, physiological feedback (based on CO levels), training in self-control strategies, stimulus control, management of craving with alternative activities, diaphragmatic breathing, weekly personalized physical activity objectives, and relapse prevention strategies. The protocol consists of a nicotine fading procedure, which consists of a weekly reduction in nicotine intake of 30% (based on both tobacco brands and the number of cigarettes) from the first to the fifth session.
Study NCT06629467 — intervention group
Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Cognitive-behavioral therapy for smoking cessation
Description: Treatment components will include psychoeducation on the consequences of tobacco use and the benefits of quitting; therapeutic commitment; self-monitoring of cigarette smoking; brief advice on healthy eating behaviors and sleep hygiene, physiological feedback (based on CO levels), training in self-control strategies, stimulus control, management of craving with alternative activities, diaphragmatic breathing, weekly personalized physical activity objectives, and relapse prevention strategies. The protocol consists of a nicotine fading procedure, which consists of a weekly reduction in nicotine intake of 30% (based on both tobacco brands and the number of cigarettes) from the first to the fifth session.
Study NCT06629467 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Personalized PA plan
Description: The treatment provider will fix an objective (e.g. go for brisk walking for 30 minutes 3 times this week) for each participant every week according to his/her current PA level, time availability, likes, and fitness level.
Study NCT06629467 — intervention group
Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Personalized PA plan
Description: The treatment provider will fix an objective (e.g. go for brisk walking for 30 minutes 3 times this week) for each participant every week according to his/her current PA level, time availability, likes, and fitness level.
Study NCT06629467 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Fitbit Versa 3
Description: Wearable activity tracker with the functionalities of a watch function, including time, date, calendar, and weather (connection to the internet is required). Physical activity monitoring (steps per day, active minutes per day, plants climbed, heart rate monitoring, time, intensity, caloric expenditure, and exercise type of exercise session), sleep monitoring (sleep time, sleep phases time, sleep quality), stress levels managing and guided breathing application are the main health-related functionalities.
Study NCT04923412 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Pulmonary branch of vagus nerve not preserved
Description: During the mediastinal lymph node dissection using minimally invasive surgery, efforts to preserve the pulmonary branch of vagus nerve is not made/ can be severed.
Study NCT06246422 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Tranexamic Acid 500 MG
Description: Local instillation of 500 mg tranexamic acid in 20 ml normal saline in the gall bladder bed
Study NCT06246422 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Normal saline
Description: Local instillation of 20 ml normal saline in the gall bladder bed
Study NCT06491095 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: OTHER
Intervention: 0 g Flax
Description: 175 g yogurt with no flax product
Study NCT06491095 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: 40 g whole ground flaxseed
Description: 175 g yogurt with 40 g whole ground flaxseed
Study NCT06491095 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: 40 g roasted then ground whole flaxseed
Description: 175 g yogurt with 40 g roasted then ground whole flaxseed
Study NCT06491095 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: 40 g of whole intact flaxseeds
Description: 175 g yogurt with 40 g of whole intact flaxseeds
Study NCT06491095 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: 28 g flax hulls
Description: 175 g yogurt with 28 g flax hulls
Study NCT05459779 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Electric wheelchair with activated assistance module
Description: This evaluation will be carried out in 1 standardized test circuit composed by 9 platforms of increasing difficulty. The same day, the patient will perform the circuit 4 times, including 2 with activated assistance.
Study NCT05459779 — intervention group
Intervention type: DEVICE
Group type: OTHER
Intervention: Electric wheelchair with assistance module not activated
Description: This evaluation will be carried out in 1 standardized test circuit composed by 9 platforms of increasing difficulty. The same day, the patient will perform the circuit 4 times, including 2 without activating assistance.
Study NCT05789381 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Magnesium sulfate
Description: This drug is commonly used on labor and delivery and in the postpartum period and is easily ordered through the electronic medical record and provided. This drug requires no specific storage for research study purposes as the drug is already being administered per standard of care and national and international guidelines. The only change is in the duration of therapy. This is NOT considered an off label use of the drug and does not require any form of exemption determination. Magnesium for severe preeclampsia is often given for anywhere from 12 to 24 hours postpartum depending on the clinical scenario, provider preference, and patient symptoms/adverse reactions to the medication.
Study NCT05789381 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Magnesium sulfate
Description: This drug is commonly used on labor and delivery and in the postpartum period and is easily ordered through the electronic medical record and provided. This drug requires no specific storage for research study purposes as the drug is already being administered per standard of care and national and international guidelines. The only change is in the duration of therapy. This is NOT considered an off label use of the drug and does not require any form of exemption determination. Magnesium for severe preeclampsia is often given for anywhere from 12 to 24 hours postpartum depending on the clinical scenario, provider preference, and patient symptoms/adverse reactions to the medication.
Study NCT06247423 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Active group 10kHz
Description: For electrical stimulation in the active groups, unmodulated alternating currents with a symmetrical rectangular waveform of 10 kHz will be applied for 20 minutes. The current intensity shall be adjusted individually for each participant by increasing the current intensity until the participant reports a strong but comfortable tingling sensation just below the motor threshold. One electrode will be placed over the median and radial nerves, while the other over the radial nerve.~The intensity of the current shall be adjusted every two minutes if the tingling sensation decreases. This protocol had been used in previous studies conducted by our research group.
Study NCT06247423 — intervention group
Intervention type: DEVICE
Group type: SHAM_COMPARATOR
Intervention: Sham intervention
Description: Sham electrical stimulation will be performed with the same equipment, time, and electrodes as in the active groups without the participants and the evaluator having a view of the device screen. The intensity of the current will be increased for 30 seconds until the sensory threshold (strong but comfortable tingling sensation) will be reached and after that, the intensity will be reduced to 0 milliamperes (mA) with 30 seconds ramp down. Participants will not receive electrical current during the rest of the placebo intervention. This protocol was used in other studies with similar interventions to blind participants.
Study NCT06525597 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Stapokibart Injection
Description: IL-4Rα monoclonal antibody
Study NCT06525597 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Placebo
Study NCT04866407 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Mentha x piperita
Description: 2% solution of Mentha x piperita diluted in fractionated coconut oil for topical application will be applied to one extremity of the subjects in the 'Mentha x piperita' group.
Study NCT04866407 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Eucalyptus globulus
Description: 2% solution of Eucalyptus globulus diluted in fractionated coconut oil for topical application will be applied to one extremity of the subjects in the 'Eucalyptus globulus' group.
Study NCT05331495 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Intraoperative Hemoperfusion
Description: During the operation, the hemoperfusion device and the membrane oxygenator of the extracorporeal circulation device were operated in parallel.
Study NCT05140850 — intervention group
Intervention type: BIOLOGICAL
Intervention: neuroimaging examination,neuro-cognitive test,blood pressure,blood sample
Description: neuroimaging will be perform,neuro-cognitive will be tested,blood pressure will be monitored,blood samples will be tested
Study NCT05044130 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: ACTIVE_COMPARATOR
Intervention: High-fat mixed-meal tolerance test (HF-MMTT)
Description: The test meal consists of a standardized HF-MMTT (791 cal) with 197 g cream (38 % fat), 18 g sugar and 1 g vanilla sugar for taste (75 g fat, 25 g carbohydrate and 4 g protein)
Study NCT04835584 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: KRT-232
Description: KRT-232 is an experimental MDM2 inhibitor anticancer drug taken by mouth.
Study NCT04835584 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Dasatinib
Description: Dasatinib is a Tyrosine Kinase Inhibitor anticancer drug taken by mouth.
Study NCT04835584 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Nilotinib
Description: Nilotinib is an Tyrosine Kinase Inhibitor anticancer drug taken by mouth.
Study NCT05549024 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: 68Ga-RM26-RGD
Description: Intravenous injection of 68Ga-RM26-RGD with a dosage of approximately 1.8-2.2 MBq (0.05-0.06 mCi)/ kg.
Study NCT05549024 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: 18F-FDG
Description: 18F-FDG injection
Study NCT06300970 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Amodiaquine-artesunate (ASAQ)
Description: Oral medication given for treatment of uncomplicated plasmodium falciparum infection.
Study NCT06300970 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Artemether+Lumefantrine (AL)
Description: Oral medication given for treatment of uncomplicated plasmodium falciparum infection.
Study NCT06658496 — intervention group
Intervention type: DEVICE
Intervention: Near Infrared Spectroscopy
Description: Application of regional NIRS sensors to brain and kidney sites in the first 72 hours after birth to monitor regional tissue oxygenation.
Study NCT06593912 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Early Functional Training
Description: Early functional training after 3 weeks using Air Stirrup compared to cast (standard protocol) after peroneal tendon surgery.
Study NCT06593912 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Standard protocol
Description: Cast 6 weeks after peroneal tendon surgery (standard protocol)
Study NCT05050929 — intervention group
Intervention type: RADIATION
Group type: ACTIVE_COMPARATOR
Intervention: Targeting All Brain Metastases
Description: Volumetric Modulated Arc Therapy
Study NCT05050929 — intervention group
Intervention type: RADIATION
Group type: EXPERIMENTAL
Intervention: Targeting All Brain Metastases
Description: Volumetric Modulated Arc Therapy
Study NCT04543201 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Early START visit using checklist over telephone or zoom
Description: Prior to visit subject receives pre-visit educational guide and copy of advance directive form~Follow up surveys:~Immediate: provider feedback survey~2-4 weeks after visit: subject feedback survey and caregiver/family feedback survey~After subject death: caregiver/family survey
Study NCT04789681 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Canakinumab
Description: Given SC
Study NCT04789681 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Quality-of-Life Assessment
Description: Ancillary studies
Study NCT05184803 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Docetaxel injection, oxaliplatin, S-1
Description: As a prior chemotherapy, intravenous administration is performed every 3 weeks for docetaxel 50 mg/m2 D1, intravenous administration for oxaliplatin 100 mg/m2 D1, and oral administration twice a day for S-140 mg/m2 D1 to 14.
Study NCT05549024 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: 68Ga-RM26
Description: Intravenous injection of 68Ga-RM26-RGD with a dosage of approximately 1.8-2.2 MBq (0.05-0.06 mCi)/ kg.
Study NCT05549024 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: 68Ga-RGD
Description: Intravenous injection of 68Ga-RGD with a dosage of approximately 1.8-2.2 MBq (0.05-0.06 mCi)/ kg.
Study NCT05207787 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: HS-10365
Description: Single or multiple dose(s) of HS-10365 daily or twice every day. Participants will continue treatment until the end of the study in the absence of unacceptable toxicities and/or unequivocal disease progression.
Study NCT05814640 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Fluoxetine
Description: Commonly used oral antipsychotics intervention therapy.
Study NCT05814640 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Sertraline
Description: Commonly used oral antipsychotics intervention therapy.
Study NCT05814640 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Vortioxetine
Description: Commonly used oral antipsychotics intervention therapy.
Study NCT05814640 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Duloxetine
Description: Commonly used oral antipsychotics intervention therapy.
Study NCT05814640 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Aripiprazole
Description: Commonly used oral antipsychotics intervention therapy.